Catalog No.
Product Name
Application
Product Information
Citations
-
αLβ2 Integrin Inhibitor
αLβ2 integrin-IN-1 is an inhibitor of the αLβ2 integrin, designed to obstruct αLβ2 integrin-mediated cell adhesion. This compound is valuable for investigating the role of αLβ2 integrin in various inflammatory conditions and can aid in exploring therapeutic interventions for diseases characterized by aberrant cell adhesion and migration. Its application can enhance understanding of the molecular mechanisms underlying inflammatory responses. -
Integrin Inhibitor
αvβ1 integrin-IN-2 is a highly effective inhibitor of integrins αvβ1 and α5β1, exhibiting IC50 values of 0.9 nM and 33 nM, respectively. This compound also demonstrates inhibitory activity against additional integrins, including IC50s of 380 nM for αvβ3, 280 nM for αvβ5, 230 nM for αvβ6, and 87 nM for αvβ8, as determined by the SPRA assay. αvβ1 integrin-IN-2 is valuable for research applications focused on integrin-mediated signaling pathways and cell adhesion processes. -
Integrin Anagonist
Ac-RGDS-NH2 is a tetrapeptide that serves as an integrin antagonist. It exhibits competitive binding to the GPIIb/IIIa receptor with a Ki of 4.2 μM, effectively inhibiting the interaction of fibrinogen with platelets and consequently suppressing platelet aggregation. This reagent is suitable for research applications related to thrombosis and platelet function studies. -
Integrin Inhibitor
Gly-Arg-Gly-Asp-Ser TFA is a pentapeptide that serves as an integrin inhibitor. It effectively binds to the integrin receptors αvβ3 and αvβ5, exhibiting an estimated IC50 of approximately 5 μM and 6.5 μM, respectively. This compound is valuable in research applications focused on cell adhesion, migration, and signaling processes relevant to various pathologies, including cancer and tissue engineering. -
αvβ6 Integrin Inhibitor
GSK3335103 is an orally active, non-peptide inhibitor of the αvβ6 integrin, demonstrating a potent affinity with a pIC50 value of 8. This compound is primarily utilized in research focused on pulmonary fibrosis, aiding in the understanding of its pathophysiology and potential therapeutic interventions. The inhibition of αvβ6 integrin by GSK3335103 can provide insights into cellular mechanisms involved in fibrotic processes. -
Integrin Antagonist
UR-2922 is an integrin antagonist that selectively targets the GPIIb/IIIa receptor on platelets. This compound exhibits potent antiplatelet aggregation activity, making it a useful tool for research into cardiovascular diseases. With its high affinity for human platelet receptors and favorable pharmacokinetic properties, UR-2922 is ideal for studies aimed at understanding and inhibiting cardiovascular pathophysiology. -
alpha V Integrin Antagonist
JNJ-26076713 is a potent and orally active antagonist of alpha V integrins, showing IC50 values of 2.3 nM for alpha(V)beta(3) and 6.3 nM for alpha(V)beta(5). This compound effectively inhibits retinal neovascularization, making it a valuable tool for research in vascular biology and potential therapeutic applications in ocular diseases. Its specificity for alpha V integrins positions JNJ-26076713 as a significant reagent for studying integrin-mediated processes. -
Integrin α4β1 Inhibitor
TBC3486 is a selective inhibitor of integrin α4β1. This compound enhances the sensitivity of leukemia cells to chemotherapy, demonstrating its potential as a chemosensitizer. TBC3486 shows efficacy in preclinical models related to integrin α4-dependent inflammatory and autoimmune conditions, notably in a mouse model of autoimmune encephalomyelitis. It is a valuable reagent for research focused on precursor B-cell acute lymphoblastic leukemia. -
α4 integrin Inhibitor
6-B345TTQ is an α4 integrin inhibitor that disrupts the interaction between α4 integrin and Leupaxin. This compound exhibits significant potential in the study of inflammatory processes and related pathways. Its inhibitory activity on α4 integrin places it at the forefront of research involving immune modulation and inflammation-related conditions. -
Integrin αvβ3 Ligand
c-RGD-SH is a selective ligand for integrin αvβ3, playing a crucial role in tumor cell adhesion and migration. When conjugated with core-crosslinked polymeric micelles (CCPM), it can be utilized to synthesize a dual modality nanoparticle probe. This probe, labeled with Cy7 and 111In, facilitates both SPECT and near-infrared fluorescence (NIRF) imaging in tumor research applications, enabling enhanced visualization and targeting of cancerous tissues. -
Integrin Receptors Inhibitor
Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide functioning as an integrin receptor inhibitor. It effectively downregulates oxidative stress and restores homeostasis, targeting three integrin receptors associated with dry age-related macular degeneration (AMD). This compound is valuable for research applications focused on retinal health and the mechanisms underlying AMD. -
αvβ6 Integrin Inhibitor
αvβ6 integrin inhibitor 2 is a selective inhibitor of the αvβ6 integrin, demonstrating an IC50 of 96.5 nM. This compound effectively modulates integrin-mediated cell adhesion and signaling pathways, making it valuable for research in cancer metastasis, fibrosis, and tissue regeneration. Its ability to inhibit αvβ6 integrin activity positions it as a crucial tool for studying integrin-related biological processes. -
Integrin
Arg-Gly-Asp TFA is a synthetic peptide that targets integrins, specifically interacting with αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, α8β1, and α5β1. This peptide is crucial for mediating cell adhesion and serves as a fundamental component in the design of radioligands and peptidomimetics. Applications include the study of integrin expression and activity in vivo, providing insights into cellular interactions and behaviors relevant to various biological processes. -
Integrin Anatgonist
L-739758 is an antagonist of the αIIbβ3 integrin, also known as platelet glycoprotein IIb/IIIa. This peptidomimetic compound mimics the RGD (arginine-glycine-aspartic acid) motif, effectively binding to αIIbβ3 integrin and interfering with the blood coagulation process. L-739758 inhibits platelet aggregation, making it valuable for research focused on thrombosis and related cardiovascular disorders. -
α4 Integrin Antagonist
Carotegrast methyl hydrochloride is a potent and selective antagonist of the α4 integrin. It demonstrates significant biological activity by inhibiting the interactions mediated by α4β1 and α4β7 integrins, effectively preventing the development of colitis in murine models. This compound is valuable for research applications in understanding inflammatory processes and exploring therapeutic strategies in autoimmune diseases. -
GPIIb/IIIa Integrin
Gantofiban is a potent antagonist of the GPIIb/IIIa integrin receptor. Its mechanism involves binding to this receptor, which leads to the inhibition of platelet aggregation, producing a significant antithrombotic effect. Gantofiban is primarily used in research related to thrombosis, cardiovascular diseases, and the study of platelet function. -
Integrin α5β1 Inhibitor
CLT-28643 is an integrin α5β1 inhibitor that plays a significant role in modulating cellular adhesion and migration. It effectively reduces the overexpression of integrin α5β1 in post-surgical blebs, thereby facilitating the wound healing process. This compound is valuable for research in tissue regeneration and healing mechanisms. -
Integrin Inhibitor
RUC-1 is a specific inhibitor of the αIIbβ3 integrin. This compound effectively inhibits fibrin deposition and platelet aggregation in mouse models expressing hybrid hαIIb/mβ3 receptors. RUC-1 demonstrates significant antithrombotic effects, making it a valuable tool for studying integrin-related processes and potential therapeutic applications in coagulation disorders. -
Integrin Antagonist
Zaurategrast ethyl ester sulfate serves as an antagonist for the α4β1 and α4β7 integrins. This compound demonstrates significant efficacy in modulating immune responses, making it a valuable tool for investigating therapeutic strategies in inflammatory and autoimmune disorders. Its mechanism of action supports research focused on the modulation of integrin-mediated cell adhesion and migration. -
Integrin Antagonist
SR121566A is a non-peptide integrin antagonist targeting Glycoprotein IIb/IIIa (GP IIb-IIIa). This compound effectively inhibits human platelet aggregation induced by ADP, arachidonic acid, and collagen, with IC50 values of 46±7.5 nM, 56±6 nM, and 42±3 nM, respectively. SR121566A is valuable for research applications focused on thrombus formation and cardiovascular diseases. -
Microtubule/Tubulin Inhibitor
D011-2120 is a microtubule/tubulin inhibitor that disrupts microtubule polymerization, interfering with the Golgi complex's function. This inhibition hampers viral trafficking to the plasma membrane, thereby blocking virus egress. D011-2120 is valuable in virology research for studying antiviral mechanisms and cellular pathways involved in viral replication and dissemination. -
KIF18A Inhibitor
Sovilnesib is a selective inhibitor of the kinesin-like protein KIF18A, exhibiting an IC50 value of 0.071 μM. This potent, orally active compound is utilized in cancer research, where it aids in the investigation of microtubule dynamics and the mechanisms of tumor cell proliferation. Sovilnesib facilitates the study of KIF18A's role in cancer progression and provides insights into potential therapeutic strategies targeting this protein. -
HSET Inhibitor
CCT368772 is a selective kinesin HSET inhibitor, demonstrating an IC50 value of 0.019 μM in the HSET ADP-Glo assay. This compound shows high selectivity for HSET, with minimal activity against Eg5 (IC50 >200 μM). CCT368772 is suitable for research into hyperproliferative diseases, including various cancer types, providing a valuable tool for understanding and potentially targeting these pathologies. -
KIF18A Inhibitor
KIF18A-IN-6 is a potent inhibitor of KIF18A, exhibiting an IC50 of 0.016 μM against KIF18A's microtubule-dependent ATPase activity. This compound is valuable for investigating the role of KIF18A in cellular processes, including mitotic spindle assembly and chromosome alignment. Researchers can utilize KIF18A-IN-6 to explore therapeutic strategies targeting cancer cell division by modulating KIF18A activity. -
KIF18A Inhibitor
KIF18A-IN-1 is a potent inhibitor of the mitotic kinesin KIF18A, demonstrating significant anti-tumor activity. By targeting KIF18A, this compound has the potential to activate mitotic checkpoints, selectively inducing apoptosis in chromosomally unstable cancer cells. It is a valuable tool for research focused on cancer biology and the development of targeted cancer therapeutics. -
KIF18A Inhibitor
AM-5308 is a potent inhibitor of KIF18A, showcasing an IC50 value of 47 nM. By inhibiting KIF18A-mediated microtubule ATPase activity, AM-5308 effectively activates mitotic checkpoints and regulates critical cell division processes, including chromosome segregation and spindle assembly. This compound demonstrates notable antitumor activity, making it a valuable tool for cancer research and studies focused on mitotic regulation. -
KIF18A Inhibitor
AM-9022 is a potent and selective inhibitor of KIF18A, primarily targeting the kinesin family of motor proteins involved in cellular transport and mitosis. This compound demonstrates significant inhibitory activity, making it a valuable tool for research into cancer mechanisms and potential therapeutic strategies. Its efficacy in modulating KIF18A function provides insights into the role of mitotic regulation in tumorigenesis. -
Kinesin-5 Inhibitor
PVZB1194 is a selective inhibitor of Kinesin-5 ATPase, targeting the α4/α6 site within the motor domain in a nucleotide-competitive manner. With an IC50 of 0.12 μM for KSP ATPase, PVZB1194 effectively induces mitotic arrest characterized by the formation of monopolar spindles, leading to inhibition of HeLa cell proliferation (IC50: 5.5 μM). This compound is valuable for research applications focusing on tumor biology and cell division regulation. -
CENP-E Inhibitor
PF-2771 is a selective inhibitor of centromere protein E (CENP-E) that inhibits its motor activity with an IC50 of 16.1 nM. This compound exhibits significant potential as an anticancer agent by disrupting mitotic processes and leading to cell cycle arrest. PF-2771 is utilized in research investigating the mechanisms of cancer cell division and has applications in the development of novel cancer therapeutics. -
KIF18A Inhibitor
KIF18A-IN-13 is a potent inhibitor of KIF18A, demonstrating significant anticancer activity in vivo. This compound is particularly applicable in research focusing on ovarian cancer, providing a valuable tool for studying the mechanisms of tumor growth and potential therapeutic interventions. -
Kinesin
BRD9876 is a kinesin-5 (Eg5) inhibitor that functions by locking the protein in a conformation with enhanced microtubule binding, promoting microtubule bundling and stabilization. It specifically interacts with the tyrosine 104 residue within the α4-α6 allosteric binding pocket of Eg5, selectively inhibiting myeloma cells while sparing CD34+ hematopoietic stem cells. This compound is a valuable tool for studying the mechanisms of multiple myeloma and developing potential therapeutic strategies. -
CENP-E Inhibitor
Syntelin is a selective inhibitor of centromere protein E (CENP-E) with an IC50 of 160 nM. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Its ability to modulate CENP-E function underscores its potential applications in studying mitotic processes and exploring therapeutic strategies for cancer treatment. -
KIFC1 Inhibitor
SR31527 chloride is a potent inhibitor of KIFC1, exhibiting an IC50 value of 6.6 µM. This compound effectively reduces cell viability and impairs colony formation in cellular assays. Its biological activity makes it a valuable tool for investigating the roles of KIFC1 in cell proliferation and cancer research. -
KIF18A Inhibitor
KIF18A-IN-2 is a selective inhibitor of KIF18A with an IC50 of 28 nM. This compound effectively induces mitotic arrest, leading to an increased population of mitotic cells in tumor tissues. KIF18A-IN-2 is suitable for use in cancer research, providing valuable insights into the mechanisms of cell division and the potential for therapeutic interventions. -
KIF18A Inhibitor
KIF18A-IN-3 is a selective inhibitor of kinesin motor protein KIF18A, with an IC50 of 61 nM. This compound induces significant mitotic arrest and enhances the population of mitotic cells within tumor tissues. KIF18A-IN-3 is suited for cancer research applications, providing insights into the roles of mitotic regulation and potential therapeutic strategies targeting KIF18A. -
KIF18A Inhibitor
KIF18A-IN-9 is a potent inhibitor of kinesin family member 18A (KIF18A), exhibiting an IC50 value of 3.8 nM. This compound demonstrates significant anticancer activity, showing IC50 values below 100 nM in ovarian cancer OVCAR3 and breast cancer MDA-MB-157 cell lines. KIF18A-IN-9 serves as a valuable tool for investigating the role of KIF18A in mitotic processes and its potential therapeutic implications in cancer research. -
KSP Inhibitor
Filanesib TFA is a selective kinesin spindle protein (KSP) inhibitor, demonstrating an IC50 of 6 nM against human KSP. This compound effectively induces apoptosis in vitro, providing potent anti-proliferative activity. Filanesib TFA is utilized in research applications focused on cancer biology and exploring novel therapeutic strategies targeting mitotic processes. -
Eg5 Inhibitor
(S)-Monastrol is an allosteric inhibitor of the mitotic kinesin Eg5, known for its ability to disrupt mitotic spindle formation. This compound exhibits significant antiproliferative activity against various cancer cell lines by inducing a monopolar spindle formation, effectively arresting mammalian cells in mitosis. (S)-Monastrol serves as a valuable tool for research into cancer biology and the mechanisms of cell division. -
Eg5 Inhibitor
SB-743921 free base is a highly selective inhibitor of the mitotic kinesin Eg5, exhibiting a Ki of 0.1 nM. This compound effectively induces mitotic arrest, inhibits cell cycle progression, and promotes apoptosis. It serves as a valuable tool in cancer research, particularly in the study of myeloma, leukemia, and other malignancies. -
Anticancer Agent
Kolavenic acid analog (KAA) is an anticancer agent that inhibits centrosome clustering in human cancer cells characterized by elevated levels of HSET and supernumerary centrosomes. KAA demonstrates significant activity against HSET-overproducing yeast cells, making it a valuable tool for understanding the role of HSET in cancer biology. This compound is suitable for research applications targeting centrosome dynamics and their implications in tumorigenesis. -
HSET Motor Inhibitor
Solidagonic acid is an HSET motor inhibitor that facilitates the conversion of abnormal monopolar spindles to bipolar spindles, thus promoting proper mitotic progression. This compound has been shown to suppress cell death in fission yeast and can revert monopolar to bipolar spindle morphology. Additionally, Solidagonic acid demonstrates growth inhibitory effects on the seedlings of Lactuca sativa L. and Lolium multiflorum Lam, making it a valuable tool for studying spindle dynamics and plant development. -
KIF18A Inhibitor
KIF18A-IN-4 is a noncompetitive inhibitor of KIF18A, targeting ATP and microtubule interactions with an IC50 of 6.16 μM. This compound demonstrates selectivity against a wide range of mitotic kinesins and kinases, while not interfering with tubulin assembly. KIF18A-IN-4 is valuable for research applications focused on tumor biology, particularly in studies investigating its anti-tumor properties. -
MKLP2 Inhibitoe
LG157 is a potent inhibitor of mitotic kinesin-like protein 2 (MKLP2), a critical motor protein involved in maintaining mitotic spindle dynamics and cytokinesis. By selectively targeting MKLP2, LG157 effectively disrupts cell division, making it a valuable reagent for research into cancer cell proliferation and related therapeutic strategies. Its application in cell biology provides insight into the mechanisms of mitotic regulation and potential treatment approaches for tumors exhibiting aberrant cell division. -
KIF18A Inhibitor
EX05 is a potent KIF18A inhibitor, exhibiting an IC50 of 8.2 nM. This compound selectively disrupts the function of KIF18A, a motor protein involved in mitotic spindle positioning, making it a valuable tool for cancer research. Its ability to interfere with cell division processes makes EX05 suitable for studying mechanisms of tumorigenesis and potential therapeutic strategies in oncology. -
KIF18A Inhibitor
KIF18A-IN-19 is a potent inhibitor of KIF18A, demonstrating an IC50 of less than 0.1 μM. This compound exhibits significant anti-cancer activity, particularly against ovarian cancer, making it a valuable tool in cancer research. Its mechanism of action and high efficacy establish KIF18A-IN-19 as a promising candidate for investigating the role of KIF18A in tumor biology. -
KIF18A Inhibitor
KIF18A-IN-12 is a potent inhibitor of KIF18A, exhibiting an IC50 value of 45.54 nM. This compound is valuable for investigating the role of KIF18A in cell division and its implications in cancer research. Researchers can utilize KIF18A-IN-12 to study the mechanistic pathways involved in tumorigenesis and explore potential therapeutic strategies targeting this kinesin. -
KIF18A Inhibitor
KIF18A-IN-14 is a selective inhibitor targeting KIF18A, a motor protein involved in spindle dynamics during cell division. This compound exhibits potent anti-proliferative effects, demonstrating IC50 values between 0-0.01 μM for the EX81-A form and 0.01-0.1 μM for its enantiomer, EX81-B, in OVCAR-3 cell lines. KIF18A-IN-14 is valuable for research applications in tumor biology, particularly in studies related to colon, breast, and lung cancers. -
S-enantiomer of AM-9022
(S)-AM-9022 is the S-enantiomer of AM-9022, functioning as a selective inhibitor of KIF18A. This compound exhibits significant potency and is utilized in cancer research, providing insights into the mechanisms of tumor progression and potential therapeutic strategies targeting kinesin motor proteins. Its application aids in understanding cell division and mitotic regulation in cancer biology. -
KIF18A Inhibitor
KIF18A-IN-10 is a potent inhibitor of KIF18A, exhibiting an IC50 value of 23.8 nM. This compound demonstrates significant anticancer activity, with IC50 values under 100 nM in ovarian cancer OVCAR3 and breast cancer MDA-MB-157 cell lines. KIF18A-IN-10 is a valuable tool for research investigating the role of KIF18A in cancer biology and potential therapeutic strategies. -
KSP Inhibitor
KSP-IA is a potent inhibitor of kinesin spindle protein (KSP), exhibiting an IC50 value of 3.6 nM. This compound effectively disrupts cell mitosis, making it a valuable tool for research in cancer biology and cellular division mechanisms. Its specificity for KSP underscores its potential in exploring therapeutic strategies that target mitotic processes.
